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K e y  M e s s a g e s 
1. A state-transition Markov model was developed 
to evaluate the cost-effectiveness of Helicobacter 
pylori screening and treatment in Hong Kong 
Chinese people, and to evaluate the uncertainty 
surrounding choice of strategies and the value of 
further research on the decision to initiate a mass 
screening programme.
2. A decision analytic framework and a societal 
perspective were adopted. The least costly and 
non-dominated strategy was H pylori serologic 
testing, followed by treating those positive for H 
pylori, with no follow-up testing. Its incremental 
cost-effectiveness ratio was US$20 547 for men 
and HK$26 840 for women per life year saved or 
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Introduction
In Hong Kong, gastric cancer is the fourth 
leading cause of cancer-related death following 
lung, colorectum, and liver cancer. Eradication 
of Helicobacter pylori may reduce the incidence 
of gastric cancer.1 This study estimated the cost-
effectiveness of H pylori screening and treatment 
in Hong Kong Chinese people, and evaluated the 
uncertainty surrounding choice of strategies and the 
value of further research on the decision to initiate a 
mass screening programme.
Methods 
Study instruments and cost-effectiveness 
analyses
This study was conducted from December 2009 to 
November 2011. A state-transition Markov model 
was developed to simulate H pylori screening and 
treatment as well as gastric cancer diagnosis and 
treatment in Hong Kong Chinese people aged 20 
years for the next 60 years. Participants were followed 
up throughout their lifetime. Disease progression 
could vary by H pylori status, sex, and age.
 According to a gastric carcinogenesis model,2 
the natural history of non-cardia intestinal-type 
gastric adenocarcinomas was characterised as a 
progression of yearly transitions among various 
health states (Fig), including normal gastric mucosa, 
gastritis, gastric atrophy, intestinal metaplasia, 
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dysplasia, early gastric cancer, distant gastric cancer, 
death from gastric cancer, and death from other 
causes. A cohort of individuals were distributed 
to either H pylori–positive or H pylori–negative 
precancerous health states. They could remain in 
one state or transit to other states at rates according 
to local-specific data and/or consensus from the 
literature. A cohort of 100 000 cancer-free 20-year-
old people over a 60-year span was modelled. It was 
assumed that gastric cancer deaths could only occur 
in those in the metastatic state.
 It was assumed that the effectiveness of H 
pylori treatment depends on the absence of advanced 
precancerous lesions and that treatment reduces 
disease progression probabilities in those with 
gastritis and atrophy.3-5 Our model was based on a 
randomised controlled trial in a Japanese population 
evaluating the effectiveness of H pylori treatment to 
prevent (metachronous) cancers among early gastric 
cancer patients after endoscopic mucosal resection.1
 Three strategies were evaluated: (1) no 
screening or treatment, (2) H pylori serologic testing, 
followed by treating those positive for H pylori, with 
no follow-up testing, (3) H pylori serologic testing, 
followed by treating those positive for H pylori, 
and confirming H pylori eradication using a C-urea 
breath test, and retreating those who were positive. 
 Four major direct medical costs were 
considered: the cost of screening for H pylori, the cost 
of treatment for H pylori, the one-time cost of invasive 
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US$17 886 for men and HK$23 905 for women 
per quality-adjusted life year (QALY) saved, 
compared with no screening or treatment.
3. H pylori screening and treatment could be cost-
effective based on the threshold of US$50 000 per 
QALY.
  #  Wong et al #
14 Hong Kong Med J  ⎥  Volume 20 Number 6 (Supplement 7)  ⎥  December 2014  ⎥  www.hkmj.org Hong Kong Med J  ⎥  Volume 20 Number 6 (Supplement 7)  ⎥  December 2014  ⎥  www.hkmj.org
cancer treatment, and the cost of terminal care 
during the final 6 months before death. The cancer 
treatment cost included diagnosis (eg endoscopy), 
major surgical procedure (eg gastrectomy), 
hospitalisation after surgery, chemotherapy, and staff 
costs. The first-line treatment for H pylori (a 14-day 
course of proton pump inhibitor, clarithromycin, and 
amoxicillin) was used. The costs of treatment were 
estimated based on per unit/month drug price and 
fees and charges in a public hospital. The terminal 
costs were calibrated according to the trajectory of 
US cancer costs. Other major non-health care costs 
were also considered, including transportation and 
time costs. All costs were adjusted to the 2012 level.
 Strategies that were less effective and more 
costly than a competing strategy were eliminated by 
simple dominance. Comparative performance of the 
remaining screening strategies was measured by the 
incremental cost-effectiveness ratio (ICER). Those 
that were less effective and had a higher ICER were 
ruled out by extended dominance and eliminated, 
and the ICERs of the remaining strategies were 
recalculated. 
 A societal perspective was adopted. 
Recommendations of the Panel on Cost-Effectiveness 
in Health and Medicine were used in performing 
cost-effectiveness calculations.
Sensitivity analysis 
A probabilistic sensitivity analysis was conducted 
to examine uncertainty surrounding choice of 
strategies. Clinical and cost parameters were 
specified with appropriate probabilistic 
distributions, and cost-effectiveness results 
associated with selecting values at random from the 
distributions were used in a Monte Carlo simulation 
of the model with 1000 runs. Based on the simulated 
cost-effectiveness results, a cost-effectiveness 
acceptability curve was constructed to present the 
uncertainty of the ICER across different values of 
the ceiling ratios (ie acceptability willingness-to-pay 
thresholds).
 The uncertainty that potentially existed in 
decision and the model parameters in value of 
information analyses were assessed. That is, the 
uncertainty surrounding choice of strategies and 
whether further research could add value to the 
decision of initiating a population-wide screening 
programme were evaluated, as was the expected 
value of perfect information (EVPI) for the entire 
cost-effectiveness model.6 
FIG.  State transition diagram for the Helicobacter pylori screening model
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TABLE.  Helicobacter pylori screening and treatment strategies for a cohort of 100 000 Hong Kong Chinese people aged 20 years for the next 60 years*
Strategy* Projected total 
mortality in the 
next 60 years
Projected 
gastric 
cancer-related 
mortality in the 
next 60 years
Lifetime costs 
(million US$)
Life years Incremental cost-effectiveness 
ratio†
Cost per life 
year saved
Cost per 
quality-adjusted 
life year saved
Men
No screening or treatment 95 100 814 23.73 5 970 700
Screening and treatment 95 091 773 35.03 5 971 250 20 547 17 886
Screening, treatment, and rescreening 95 088 759 54.03 5 971 432 104 463 90 712
Women
No screening or treatment 86 962 520 14.99 6 546 824
Screening and treatment 86 955 494 26.29 6 547 245 26 840 23 905
Screening, treatment, and rescreening 86 953 486 45.29 6 547 375 146 341 130 239
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Results 
Cost-effectiveness and associated uncertainty
Compared with no screening or treatment, screening 
and treatment for H pylori resulted in a gain in life 
expectancy of 1.2 to 2 days at an incremental cost 
of US$113 to US$303 per person (Table). The most 
cost-effective (non-dominated) strategy was H pylori 
serologic testing, followed by treating those positive 
for H pylori, with no follow-up testing. Its ICER was 
US$20 547 for men and HK$26 840 for women per 
life year saved or US$17 886 for men and HK$23 905 
for women per quality-adjusted life year (QALY) 
saved, compared with no screening or treatment. 
In probabilistic sensitivity analyses, the probability 
of the ICER being below a threshold of US$50 000 
per life year saved was 51.9% for men and 50.7% for 
women. 
Expected value of perfect information
The results of the model were subject to limited 
uncertainty (cost per man/woman=US$825/
US$790). The EVPI for the patient populations was 
estimated to be US$13.4 million over 40 years if a 
willingness-to-pay threshold was US$50 000 per life 
year saved.
Discussion
The most cost-effective strategy was H pylori 
serology testing, followed by antibiotic treatment 
for those positive, with no follow-up testing. The 
probability sensitivity analyses and the EVPI analyses 
showed the robustness of the results by considering 
several dimensions of uncertainty. The state-
transition model captured the natural history of 
non-cardia intestinal-type gastric adenocarcinoma, 
and reflected the role of H pylori infection in the 
pathogenesis of gastric cancer.
 A potential limitation of this study was that we 
did not have aggregate local stage-specific treatment 
costs for invasive gastric cancer, and instead relied 
on individual itemised cost data. In addition, we did 
not evaluate the full spectrum of screening strategies 
for H pylori (eg screening at different ages). 
 This mathematical decision analytic model 
could provide insight about the long-term outcomes 
and the cost-effectiveness of H pylori screening and 
treatment strategies. 
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